On July 16, 2025 HanchorBio Inc. (TPEx: 7827.TWO), a pioneer of immunotherapy biologics, reported its official listing on the Taipei Exchange (TPEx) Emerging Stock Board under the ticker symbol 7827.TWO and the name Hanchor-KY (Press release, Hanchor Bio, JUL 16, 2025, View Source [SID1234654416]). The company enters the public market with over USD 80 million in equity financing, backed by cumulative investments from leading global institutional investors, including Vivo Capital, Panacea Venture, and Affinity Capital. Effective on June 20, 2025, the listing marks a significant step forward for the company as momentum builds around its best-in-class CD47-targeting immunotherapy, HCB101.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

As HanchorBio actively fundraises, interested parties may contact: [email protected]

"This IPO is more than a financial milestone — it’s a defining moment for all of us at HanchorBio," said Scott Liu, PhD, Co-Founder, Chairman, and CEO of HanchorBio. "When we started this journey just a few years ago, our vision was bold: to build a next-generation immunotherapy company with global impact. Today, we are one step closer to realizing that vision with a differentiated platform; an advanced pipeline with more than six first-in-class, multifunctional fusion proteins; and encouraging clinical results. I’m incredibly grateful to our dedicated team, Board of Directors, world-class scientific advisors, and the supportive investors who have believed in us from the beginning. We believe Taiwan is uniquely positioned to nurture the next set of global leaders in precision immunotherapy, and we are proud to contribute to this transformation."

Harnessing the potential of immunotherapy

Immunotherapy for cancer treatment holds significant promise, and the global market specifically for CD47-targeting immunotherapies like HCB101 is particularly lucrative — it is projected to exceed US$40 billion by 2035, growing at a CAGR of 18%, according to Frost and Sullivan.

HanchorBio’s listing also reflects the growing role Taiwan is playing as a strategic center for biotech innovation. According to BioSpectrum Asia, Taiwan’s biotech sector is steadily expanding through coordinated efforts between government and industry.

The company’s public listing offers investors exposure to:

A validated clinical asset (HCB101) with global regulatory clearance
A next-generation biologics platform (FBDB) with broad licensing and development potential
Strategic operations across the U.S., mainland China, and Taiwan
A seasoned leadership team with over 30 IND submissions and 10 NDA/BLA filings and approvals
Growing momentum of HCB101

HanchorBio’s leading treatment, HCB101, has reached major milestones recently. It began Phase 2 clinical trials in March 2025, with participants from Taiwan, the United States, and China. In late May, the company also shared interim results from its ongoing Phase 1a dose-escalation trial (NCT05892718) at the 2025 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting. The key findings included:

Favorable safety and tolerability across escalating dose cohorts
Plasma exposure increased in a greater-than-dose-proportional manner and with increased half-life at higher doses
High-level CD47 receptor occupancy in peripheral immune cells
Early clinical signs of anti-tumor activity:
Six patients in the low-dose cohorts achieved stable disease (SD) at the best response, including one ovarian cancer patient (1.28 mg/kg) who maintained disease control for over 32 weeks.
Two patients in the higher-dose cohorts achieved confirmed partial responses (PRs):
A head and neck squamous cell carcinoma (HNSCC) patient at 5.12 mg/kg experienced a 27% tumor reduction in the sum of diameters (SOD) at Week 8, then increasing to 42% by Week 16.
A patient with Non-Hodgkin Lymphoma (NHL) at 8 mg/kg achieved a PR confirmed by PET imaging at Week 8.